dual anti-CHI3L1/anti-CTLA-4 bispecific antibody (Ocean Biomedical)

N/A

Report date: 2025/03/19 08:58:31

Base Information

Drug Namedual anti-CHI3L1/anti-CTLA-4 bispecific antibody (Ocean Biomedical)
Drug Alias Namebispecific CHI3L1 antibody/CTLA-4 checkpoint inhibitor (Ocean Biomedical)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsChitinase-3-like protein 1 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Chitinase-3-like protein 1
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOcean Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesOcean Biomedical Inc
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A